These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
943 related articles for article (PubMed ID: 26843008)
1. Sex differences in the association between AD biomarkers and cognitive decline. Koran MEI; Wagener M; Hohman TJ; Brain Imaging Behav; 2017 Feb; 11(1):205-213. PubMed ID: 26843008 [TBL] [Abstract][Full Text] [Related]
2. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease. Hohman TJ; Bell SP; Jefferson AL; JAMA Neurol; 2015 May; 72(5):520-9. PubMed ID: 25751166 [TBL] [Abstract][Full Text] [Related]
3. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease. Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875 [TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O; JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367 [TBL] [Abstract][Full Text] [Related]
5. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum. Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT; Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664 [TBL] [Abstract][Full Text] [Related]
6. Sex differences in CSF biomarkers vary by Alzheimer disease stage and Babapour Mofrad R; Tijms BM; Scheltens P; Barkhof F; van der Flier WM; Sikkes SAM; Teunissen CE Neurology; 2020 Oct; 95(17):e2378-e2388. PubMed ID: 32788242 [TBL] [Abstract][Full Text] [Related]
7. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid. Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990 [TBL] [Abstract][Full Text] [Related]
8. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028 [TBL] [Abstract][Full Text] [Related]
9. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL; Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169 [TBL] [Abstract][Full Text] [Related]
10. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM; J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495 [TBL] [Abstract][Full Text] [Related]
11. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients. Knapskog AB; Eldholm RS; Braekhus A; Engedal K; Saltvedt I BMC Geriatr; 2017 Sep; 17(1):210. PubMed ID: 28893185 [TBL] [Abstract][Full Text] [Related]
12. The Role of Amyloid, Tau, and APOE Genotype on the Relationship Between Informant-Reported Sleep Disturbance and Alzheimer's Disease Risks. Kim H; Levine A; Cohen D; Gehrman P; Zhu X; Devanand DP; Lee S; Goldberg TE; J Alzheimers Dis; 2022; 87(4):1567-1580. PubMed ID: 35491776 [TBL] [Abstract][Full Text] [Related]
13. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults. Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824 [TBL] [Abstract][Full Text] [Related]
14. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. van Maurik IS; Zwan MD; Tijms BM; Bouwman FH; Teunissen CE; Scheltens P; Wattjes MP; Barkhof F; Berkhof J; van der Flier WM; JAMA Neurol; 2017 Dec; 74(12):1481-1491. PubMed ID: 29049480 [TBL] [Abstract][Full Text] [Related]
15. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers. Hake A; Trzepacz PT; Wang S; Yu P; Case M; Hochstetler H; Witte MM; Degenhardt EK; Dean RA; Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563 [TBL] [Abstract][Full Text] [Related]
16. Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease. Pettigrew C; Soldan A; Sloane K; Cai Q; Wang J; Wang MC; Moghekar A; Miller MI; Albert M; Neuroimage Clin; 2017; 16():439-446. PubMed ID: 28879085 [TBL] [Abstract][Full Text] [Related]